- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions
European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- (R)-1-[1-(4-acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyrid
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
(R)-1-[1-(4-acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea
| EU orphan designation number: | EU/3/15/1588
|
| Active ingredient: | (R)-1-[1-(4-acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea |
| Indication: | Treatment of gastro-entero-pancreatic neuroendocrine tumours |
| Sponsor: | Trio Medicines Ltd
Hammersmith Medicines Research, Cumberland Avenue, London NW10 7EW, United Kingdom |
Public summary of scientific opinion
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 16/12/2015 | Orphan designation | EMA/OD/147/15 | (2015)9510 of 14/12/2015 |
CONTACT
EU links
Directorate General Health & Consumers